"indian-council-of-medical-research"

CPT did not lead to reduction in progression to severe Covid-19 or all-cause mortality in the group that received CPT as compared to the group that did not receive the therapy, said ICMR study

The phase III trials will involve 26,000 volunteers across 25 centres in India, being conducted in partnership with ICMR

Suggest two studies which have explored the factors behind low mortality rate in India

India's COVID-19 tally had crossed the 20-lakh mark on August 7, 30 lakh on August 23 and 40 lakh on September 5.

Out of the total Covid-19 cases recorded on Tuesday, 6,25,857 are currently active, 72,01,070 have been discharged, while 1,19,502 lost the battle against the pandemic.

Drug gets approval for use in adults, paediatric patients of 12 years and above and weighing more than 40 kg for Covid treatment

The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to Bharat Biotech. The indigenous, inactivated vaccine is developed and manufactured in Bharat Biotech’s BSL-3 (Bio-Safety Level 3)

"The active cases of coronavirus infection dropped below eight lakh for the first time in one-and-half months."

The COVID-19 case fatality rate was recorded at 1.54 per cent.

According to the ICMR, a cumulative total of 8,34,65,975 samples have been tested up to October 7 with 11,94,321 samples being tested on Wednesday.

With 986 deaths, the toll due to the disease in the country now stands at 1,04,555.

Out of the total cases, 9,19,023 are currently active, 56,62,490 have been discharged, while 1,03,569 lost the battle against the viral disease.

As per the MoHFW on Sunday, the COVID-19 count is at 65,49,374, including 9,37,625 active cases in the country.